American Biogenetic Sciences

Headquartered in Copiague, New York, American Biogenetic Sciences, Inc. (ABS) adopts a dual strategy focused on the development and commercialization of diagnostic tests for cardiovascular and infectious diseases, as well as treatments for neurological disorders such as epilepsy, migraine, mania, Parkinson's disease, and Alzheimer's disease. ABS also seeks new technologies and conducts research and development within its global scientific network across the United States, Europe, Israel, Russia, and China. The company’s supporting technology includes a patented Antigen-Free mouse colony that enables the generation of highly specific monoclonal antibodies (Mabs), which traditional systems are unable to produce.